Device Executives and the Responsible Corporate Officer Doctrine: Who Could Have Stopped the Sale?

The medical device responsible corporate officer doctrine can hold an executive personally responsible for a company’s Food, Drug, and Cosmetic Act violation when the executive had the authority to prevent or correct it, even without knowing about the specific unlawful acts. For someone in quality, regulatory affairs or sales, that puts a familiar question at the center of the case: who could have stopped it? The answer can involve the person who controlled a product launch, the sales operation or the response to a Food and Drug Administration warning.

Acclarent marketed a saline sinus spacer for steroid delivery, according to the criminal trial account. In Norian’s criminal case, the government described a test market for spinal cement despite a warning against that use. Both cases followed decisions inside the manufacturer to the device that reached the physician.

What Is the Responsible Corporate Officer Doctrine?

The responsible corporate officer doctrine puts responsibility on an officer with the power to prevent or correct a violation. That means looking for problems and preventing them, as well as fixing violations already underway. What matters is who had that power over the work, beyond the title on an organization chart.

For an insider, authority has a practical meaning. Who controlled the proposed use? Who could change the sales instructions? Who received the regulatory response? The Acclarent and Norian cases connect those business decisions to the device that reached the physician.

Acclarent’s Device Changed Use Before It Had the Clearance

Acclarent’s Stratus device was cleared as a sinus spacer for use with saline, but the criminal case concerned its marketing for steroid delivery. The First Circuit’s account of the criminal trial describes the gap between the cleared use and the use the company intended to sell.

The saline spacer maintained an opening created by sinus surgery. A request to broaden its use put the company’s proposed change directly before FDA.

The company already had a clearance to point to. The question was what that clearance covered.

The Chief Executive’s Regulatory Strategy and Verdict

A jury convicted Acclarent’s chief executive in 2016 on ten misdemeanor counts concerning the unlawful distribution of Stratus. The jury acquitted him of conspiracy and the remaining wire-fraud charges and found no intent to defraud or mislead on the device counts.

The regulatory sequence in his criminal case began with clearance for saline use. The court described what the company sought next:

The Food and Drug Administration rejected the request and required a new submission for the changed intended use. The jury convicted on that missing clearance.

The Sales Leader’s Promotion and Verdict

The jury also convicted Acclarent’s vice president of sales on ten misdemeanor device counts. It acquitted him of conspiracy and the remaining wire-fraud charges. The court described evidence of promotion alongside internal marketing communications, product design and regulatory strategy. What the executives said about Stratus helped show how they intended it to be used.

The jury’s decision was narrower than the prosecution’s full account:

The promotional material showed the intended use, while the FDA correspondence showed what authorization that use needed.

The Company’s Civil Settlement Followed the Provider’s Claim

Acclarent’s separate civil settlement in July 2016 required $18 million to resolve allegations about the resulting provider claims. A whistleblower brought the civil case. The government alleged that marketing and distributing the sinus spacer for unauthorized drug delivery caused health care providers to submit false claims to Medicare and other federal healthcare programs.

The civil allegation followed the product beyond the sales conversation to the provider’s bill. The alleged cost reached taxpayers through claims for a use the Food and Drug Administration had not authorized. The executives’ criminal case concerned distributing the device; the company’s False Claims Act settlement concerned the government bills it allegedly caused.

Norian’s Test Market Reached the Executive Offices

In Norian’s criminal case, the government described promotion of Norian XR and Norian SRS bone cement for spinal fractures despite an express warning against that use on the XR label. Patients underwent the very spinal procedures the label warned against.

The criminal charging account described a test market through which the company would evaluate safety and effectiveness in unapproved clinical trials. According to the information, the company wanted to reach the market before competitors and generate published studies that would persuade more surgeons to use the cement in the spine. The proposed studies were part of the sales strategy.

The government’s account of the criminal case also described earlier laboratory work showing that the cement caused blood clots when mixed with human blood, and animal work showing clots lodging in the lungs. The company had that safety information before the marketing program began.

The government identified executives in company leadership, operations, and regulatory and clinical affairs as responsible corporate officers. Business leaders and the regulatory and clinical affairs director entered misdemeanor guilty pleas in the criminal case.

Those roles show why this subject reaches beyond the chief executive. The people responsible for operating the business and handling regulatory affairs can sit directly in the path between a safety concern and continued distribution.

The separate civil agreement required Synthes to pay $138,000 over allegations of false safety and effectiveness representations about the cement. Those representations allegedly caused government claims or purchases for spinal procedures involving Medicare, TRICARE and Department of Veterans Affairs beneficiaries. The civil payment addressed the government’s bills for a use the cement’s own label warned against.

An Acquittal and a Dismissal Tell Different Stories

Vascular Solutions and Stryker Biotech show different outcomes for executives: a jury acquitted the former company’s chief executive, while charges against the latter company’s employees were dismissed.

Vascular Solutions agreed to a $520,000 civil settlement in 2014 over allegations that it marketed its Vari-Lase device for perforator-vein ablation despite a failed trial and lack of Food and Drug Administration authorization for that use. In the separate criminal trial in 2016, the jury acquitted the company and its chief executive on all five counts.

The civil whistleblower complaint shows the kind of sales instruction an employee might recognize. It alleged that representatives recommended scheduling treatment to increase reimbursement:

That allegation connects a manufacturer’s instructions to the timing of the provider’s bill. It remains the whistleblower’s allegation, separate from the criminal jury’s acquittal.

Stryker Biotech’s criminal indictment alleged promotion of mixtures of its OP-1 products with Calstrux, including instructions to surgeons and technicians on how to prepare them. Stryker Corporation’s 2012 annual filing reported that the resolution included a corporate misdemeanor and dismissal of all charges against the then-current and former employees.

Court Orders Can Bind the Officer Running the Business

A Food and Drug Administration civil court order can put duties on the officer currently responsible for operations. Pharmaceutical Innovations illustrates that distinction. Its court order records that a new president and chief executive had no involvement in the company’s operations before taking over, but consented to being named because he was then the person most responsible for those operations.

What Evidence Is Needed to Prove Fraud?

A device whistleblower case connects the company’s decisions to a false government-payment claim and to what the responsible people knew. Food and Drug Administration correspondence, marketing instructions and sales records explain the manufacturer side. Clinical records and the provider’s bill explain how the device was used and what the government was asked to pay.

The industry splits those records across participants. A physician may strongly influence the brand and type of implant, while the hospital or surgery center buys it. Under consignment, the manufacturer can retain ownership until use. Medicare commonly pays for an implant within the procedure payment. The manufacturer’s invoice and the hospital’s claim therefore describe different transactions.

The operating-room representative can see the point where they meet: product selection, inventory and clinical use. Nursing guidance calls for the representative’s presence to be documented in the intraoperative record. That record can connect the company’s field activity to a particular procedure, while the sales and regulatory records explain the instructions behind it.

The 2020 A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting, explains that False Claims Act responsibility follows the payment claim, including when someone deliberately avoids learning whether it is false or recklessly ignores that question. For a device insider, that brings the inquiry back to the instructions, the warnings and the claim they helped produce.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Who Could Have Stopped It

If you saw executives keep selling a device after FDA rejected the use they were promoting, tell our whistleblower experts what reached management and what happened next. Your knowledge of the sales instructions and the people who could change them gives us a way into the decisions behind the provider’s claims. We build that case alongside you, bring in medical device whistleblower lawyers experienced in pursuing manufacturers, and remain your partners throughout.